Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Medicago Successfully Produces COVID-19 Vaccine Candidate
Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, said on March 12 that it has successfully produced a viable vaccine candidate for COVID-19 just 20 days after obtaining the gene of the novel coronavirus causing the disease. Medicago said that…
To read the full story
Related Article
- Medicago Inks COVID-19 Vaccine Deal with Canadian Govt
October 27, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- Medicago, GSK Team Up to Develop Adjuvanted COVID-19 Vaccine, PI to Commence in Mid-July
July 9, 2020
- Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
May 19, 2020
- Govt Officials Urge Japan Pharma Companies to Be More Proactive in Coronavirus Vaccine Development
May 12, 2020
BUSINESS
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Nxera’s Partner Earns Taiwan Approval for Daridorexant
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…